Furthermore, we also performed DSS (P < .001; Fig. 3B), PFI (P < .001; Fig. 3C), and DFS (P = 7e–04; Fig. 3D), which was consistent with the result of OS revealing the survival benefit in ccRCC patients with higher than median expression levels of SLC22A8 gene. This evidence concerns the gene SLC22A8 and nonpapillary renal cell carcinoma.